Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

N. Harbeck, E. Ciruelos, et al.

The phase 3b/4 DESTINY-Breast12 study revealed promising results for trastuzumab deruxtecan (T-DXd) in HER2+ metastatic breast cancer patients, showing significant efficacy regardless of brain metastases status. Conducted by a team of expert researchers, this study highlights T-DXd's substantial and durable intracranial activity, emphasizing its potential in previously treated patients.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

K. Shitara, Y. Bang, et al.

Medicine and Health

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

J. Cortés, S. A. Hurvitz, et al.

Medicine and Health

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

M. Schuler, K. Cuppens, et al.

Medicine and Health

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study

J. An, X. Li, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny